Accuitive Medical Ventures

Accuitive Medical Ventures is a venture capital firm based in Atlanta, founded in 2003. It specializes in financing and supporting the development of early and expansion stage companies within the medical device and technology sectors in the United States. By targeting innovative medical technology firms, Accuitive Medical Ventures aims to foster advancements that can improve healthcare outcomes.

Brandon Miller

Analyst

51 past transactions

MyoScience

Venture Round in 2018
MyoScience Inc. engages in development and commercialization of technology driven dermatological products. MyoScience Inc. was founded in 2005 and is headquartered in Redwood City, California.

Intuity Medical

Debt Financing in 2018
Intuity Medical develops blood glucose monitoring systems for diabetes management. Their POGO Automatic Blood Glucose Monitoring System is the world’s first FDA-cleared automatic, one-step blood glucose meter that combines lancing, blood collection, and analysis into a single 10-test cartridge. It provides a convenient and discreet solution for millions of patients who need to regularly test their blood glucose. The company was founded in 2002 and is headquartered in Fremont, California.

Sebacia

Series D in 2017
Sebacia, Inc. is a private medical device company dedicated to creating breakthrough topical therapies for the treatment of dermatological conditions affecting millions of people. Sebacia's goal is to provide a better alternative to the daily use of topical and systemic drugs currently available for the treatment of acne. Sebacia's patented microparticles technology was invented at Rice University, and the proprietary dermatology applications were further developed with researchers from the Wellman Center of Photomedicine at Massachusetts General Hospital. Sebacia is located in Duluth, Georgia.

Intuity Medical

Venture Round in 2016
Intuity Medical develops blood glucose monitoring systems for diabetes management. Their POGO Automatic Blood Glucose Monitoring System is the world’s first FDA-cleared automatic, one-step blood glucose meter that combines lancing, blood collection, and analysis into a single 10-test cartridge. It provides a convenient and discreet solution for millions of patients who need to regularly test their blood glucose. The company was founded in 2002 and is headquartered in Fremont, California.

Torax Medical

Series E in 2016
Torax Medical, Inc. develops and markets products/devices to restore the barrier function of sphincters. The company’s products include LINX, a reflux management system to treat patients diagnosed with gastroesophageal reflux disease; and FENIX, a continence restoration system for the treatment of fecal incontinence. It sells its products in Europe and the United States. Torax Medical, Inc. was founded in 2002 and is based in Shoreview, Minnesota. As of March 23, 2017, Torax Medical, Inc. operates as a subsidiary of Ethicon, Inc.

Sebacia

Series C in 2015
Sebacia, Inc. is a private medical device company dedicated to creating breakthrough topical therapies for the treatment of dermatological conditions affecting millions of people. Sebacia's goal is to provide a better alternative to the daily use of topical and systemic drugs currently available for the treatment of acne. Sebacia's patented microparticles technology was invented at Rice University, and the proprietary dermatology applications were further developed with researchers from the Wellman Center of Photomedicine at Massachusetts General Hospital. Sebacia is located in Duluth, Georgia.

AcuFocus

Venture Round in 2014
AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at enhancing near vision. The company offers the KAMRA inlay, designed to assist presbyopic patients in restoring their near vision while preserving distance clarity. Additionally, AcuFocus provides the IC-8 IOL, a small aperture lens that accommodates a range of vision for cataract patients. The AcuTarget HD system serves as a diagnostic and surgical planning tool, aiding in the optimal treatment selection for various eye conditions, including LASIK and dry eye. AcuFocus markets its products through distribution partners across the Americas, Asia-Pacific, Europe, and the Middle East, thereby serving a global clientele of physicians and patients. Founded in 2001, AcuFocus continues to focus on advancing solutions for presbyopia and related vision issues.

Intuity Medical

Venture Round in 2014
Intuity Medical develops blood glucose monitoring systems for diabetes management. Their POGO Automatic Blood Glucose Monitoring System is the world’s first FDA-cleared automatic, one-step blood glucose meter that combines lancing, blood collection, and analysis into a single 10-test cartridge. It provides a convenient and discreet solution for millions of patients who need to regularly test their blood glucose. The company was founded in 2002 and is headquartered in Fremont, California.

AqueSys

Series D in 2014
AqueSys, Inc. is an ophthalmic company based in Aliso Viejo, California, that specializes in developing and commercializing innovative implantable devices for glaucoma treatment. The company's primary product, the XEN gel stent, facilitates the outflow of aqueous humor from the anterior chamber to the subconjunctival space, effectively lowering intraocular pressure in patients with glaucoma. Established in 2005, AqueSys operates as a subsidiary of Allergan plc, focusing on addressing the challenges associated with managing glaucoma through its advanced medical technology. The XEN gel stent represents a significant advancement in glaucoma treatment, providing an alternative pathway for excess fluid to exit the eye and enhancing patient outcomes.

MyoScience

Series E in 2013
MyoScience Inc. engages in development and commercialization of technology driven dermatological products. MyoScience Inc. was founded in 2005 and is headquartered in Redwood City, California.

Nevro

Series C in 2013
Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza system is the only SCS system that delivers Nevro's proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro.

Torax Medical

Series D in 2012
Torax Medical, Inc. develops and markets products/devices to restore the barrier function of sphincters. The company’s products include LINX, a reflux management system to treat patients diagnosed with gastroesophageal reflux disease; and FENIX, a continence restoration system for the treatment of fecal incontinence. It sells its products in Europe and the United States. Torax Medical, Inc. was founded in 2002 and is based in Shoreview, Minnesota. As of March 23, 2017, Torax Medical, Inc. operates as a subsidiary of Ethicon, Inc.

Intuity Medical

Venture Round in 2012
Intuity Medical develops blood glucose monitoring systems for diabetes management. Their POGO Automatic Blood Glucose Monitoring System is the world’s first FDA-cleared automatic, one-step blood glucose meter that combines lancing, blood collection, and analysis into a single 10-test cartridge. It provides a convenient and discreet solution for millions of patients who need to regularly test their blood glucose. The company was founded in 2002 and is headquartered in Fremont, California.

Halscion

Debt Financing in 2012
Halscion, Inc. specializes in the development of innovative hydrogel scaffolds designed to enhance wound healing and improve scar outcomes. The company's flagship product is a single-use hydrogel scaffold that is injected during surgical procedures at the dermal-subdermal interface of wounds. This device facilitates the migration of the patient’s own cells, such as fibroblasts, into the wound in a structured manner, promoting more effective healing. Established in 2005, Halscion is headquartered in Suwanee, Georgia.

NeoVista

Venture Round in 2012
NeoVista Inc is dedicated to the development of medical technologies that help to advance the treatment of wet age-related macular degeneration (AMD). Wet AMD affects more than 5 million people around the world and is a major cause of blindness in men and women over the age of 50. The unique technology being developed by NeoVista continues to show promise in clinical studies. It is our goal to help improve the quality of care and reduce the burden of this destructive condition on patients, physicians, and the healthcare system.

MyoScience

Series D in 2012
MyoScience Inc. engages in development and commercialization of technology driven dermatological products. MyoScience Inc. was founded in 2005 and is headquartered in Redwood City, California.

AcuFocus

Venture Round in 2011
AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at enhancing near vision. The company offers the KAMRA inlay, designed to assist presbyopic patients in restoring their near vision while preserving distance clarity. Additionally, AcuFocus provides the IC-8 IOL, a small aperture lens that accommodates a range of vision for cataract patients. The AcuTarget HD system serves as a diagnostic and surgical planning tool, aiding in the optimal treatment selection for various eye conditions, including LASIK and dry eye. AcuFocus markets its products through distribution partners across the Americas, Asia-Pacific, Europe, and the Middle East, thereby serving a global clientele of physicians and patients. Founded in 2001, AcuFocus continues to focus on advancing solutions for presbyopia and related vision issues.

Intuity Medical

Series D in 2011
Intuity Medical develops blood glucose monitoring systems for diabetes management. Their POGO Automatic Blood Glucose Monitoring System is the world’s first FDA-cleared automatic, one-step blood glucose meter that combines lancing, blood collection, and analysis into a single 10-test cartridge. It provides a convenient and discreet solution for millions of patients who need to regularly test their blood glucose. The company was founded in 2002 and is headquartered in Fremont, California.

Nevro

Series B in 2011
Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza system is the only SCS system that delivers Nevro's proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro.

WaveTec Vision

Series D in 2011
WaveTec Vision is a small company with a big idea – and the ability and the team to achieve it. Their proprietary intraoperative aberrometer system ORange will transform and advance the emerging convergence of refractive and cataract surgery. It was founded in 1997 and headquartered in Aliso Viejo, California.

Halscion

Venture Round in 2011
Halscion, Inc. specializes in the development of innovative hydrogel scaffolds designed to enhance wound healing and improve scar outcomes. The company's flagship product is a single-use hydrogel scaffold that is injected during surgical procedures at the dermal-subdermal interface of wounds. This device facilitates the migration of the patient’s own cells, such as fibroblasts, into the wound in a structured manner, promoting more effective healing. Established in 2005, Halscion is headquartered in Suwanee, Georgia.

NeoVista

Series E in 2011
NeoVista Inc is dedicated to the development of medical technologies that help to advance the treatment of wet age-related macular degeneration (AMD). Wet AMD affects more than 5 million people around the world and is a major cause of blindness in men and women over the age of 50. The unique technology being developed by NeoVista continues to show promise in clinical studies. It is our goal to help improve the quality of care and reduce the burden of this destructive condition on patients, physicians, and the healthcare system.

Respicardia

Series C in 2010
Respicardia (formerly Cardiac Concepts) is dedicated to improving the lives of heart failure patients by developing implantable therapies designed to improve respiratory rhythm management and cardiovascular health. The first product, the remedē® System, is an implantable stimulation device that is designed to restore a more normal breathing pattern during sleep for patients with central sleep apnea. Respicardia® is committed to improving cardiovascular health…one breath at a time™.

AqueSys

Series C in 2010
AqueSys, Inc. is an ophthalmic company based in Aliso Viejo, California, that specializes in developing and commercializing innovative implantable devices for glaucoma treatment. The company's primary product, the XEN gel stent, facilitates the outflow of aqueous humor from the anterior chamber to the subconjunctival space, effectively lowering intraocular pressure in patients with glaucoma. Established in 2005, AqueSys operates as a subsidiary of Allergan plc, focusing on addressing the challenges associated with managing glaucoma through its advanced medical technology. The XEN gel stent represents a significant advancement in glaucoma treatment, providing an alternative pathway for excess fluid to exit the eye and enhancing patient outcomes.

Halscion

Venture Round in 2009
Halscion, Inc. specializes in the development of innovative hydrogel scaffolds designed to enhance wound healing and improve scar outcomes. The company's flagship product is a single-use hydrogel scaffold that is injected during surgical procedures at the dermal-subdermal interface of wounds. This device facilitates the migration of the patient’s own cells, such as fibroblasts, into the wound in a structured manner, promoting more effective healing. Established in 2005, Halscion is headquartered in Suwanee, Georgia.

Sadra Medical

Series C in 2009
Sadra Medical is dedicated to creating innovative, minimally invasive alternatives to traditional surgical valve replacement, specifically targeting the treatment of aortic valve disease. The company aims to address the significant clinical need for effective therapies, as aortic valve stenosis affects approximately 3 million individuals in the United States, yet only a small percentage receive treatment through conventional open-heart surgery. By developing new devices that facilitate these advanced procedures, Sadra Medical seeks to enhance patient care and make valve replacement accessible to a broader range of patients. The company's goal is to reduce the risks and complications associated with open surgical procedures, providing a viable therapeutic option for those who currently lack effective treatment.

Torax Medical

Series C in 2009
Torax Medical, Inc. develops and markets products/devices to restore the barrier function of sphincters. The company’s products include LINX, a reflux management system to treat patients diagnosed with gastroesophageal reflux disease; and FENIX, a continence restoration system for the treatment of fecal incontinence. It sells its products in Europe and the United States. Torax Medical, Inc. was founded in 2002 and is based in Shoreview, Minnesota. As of March 23, 2017, Torax Medical, Inc. operates as a subsidiary of Ethicon, Inc.

NovaLign Orthopaedics

Series B in 2009
NovaLign Orthopaedics formerly known as OsteoLign is an orthopaedic medical device company based in Memphis, Tenn. NovaLign recently received its first 510(k) clearance from the FDA to market its new Intramedullary Fixation System, a new system of implants and instruments for the treatment of long bone fractures, including the humerus, tibia and femur.

NeoVista

Series D in 2009
NeoVista Inc is dedicated to the development of medical technologies that help to advance the treatment of wet age-related macular degeneration (AMD). Wet AMD affects more than 5 million people around the world and is a major cause of blindness in men and women over the age of 50. The unique technology being developed by NeoVista continues to show promise in clinical studies. It is our goal to help improve the quality of care and reduce the burden of this destructive condition on patients, physicians, and the healthcare system.

WaveTec Vision

Series C in 2009
WaveTec Vision is a small company with a big idea – and the ability and the team to achieve it. Their proprietary intraoperative aberrometer system ORange will transform and advance the emerging convergence of refractive and cataract surgery. It was founded in 1997 and headquartered in Aliso Viejo, California.

CELLutions Biosystems

Series B in 2008
Cellutions is developing proprietary medical devices and procedures to treat cellulite, a condition that affects 90% of post-adolescent females. The company is developing a proprietary technology/procedure to be performed in an outpatient setting as a minimally invasive ‘lunchtime' treatment.

Respicardia

Series B in 2008
Respicardia (formerly Cardiac Concepts) is dedicated to improving the lives of heart failure patients by developing implantable therapies designed to improve respiratory rhythm management and cardiovascular health. The first product, the remedē® System, is an implantable stimulation device that is designed to restore a more normal breathing pattern during sleep for patients with central sleep apnea. Respicardia® is committed to improving cardiovascular health…one breath at a time™.

Nevro

Series A in 2008
Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza system is the only SCS system that delivers Nevro's proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro.

AqueSys

Series B in 2008
AqueSys, Inc. is an ophthalmic company based in Aliso Viejo, California, that specializes in developing and commercializing innovative implantable devices for glaucoma treatment. The company's primary product, the XEN gel stent, facilitates the outflow of aqueous humor from the anterior chamber to the subconjunctival space, effectively lowering intraocular pressure in patients with glaucoma. Established in 2005, AqueSys operates as a subsidiary of Allergan plc, focusing on addressing the challenges associated with managing glaucoma through its advanced medical technology. The XEN gel stent represents a significant advancement in glaucoma treatment, providing an alternative pathway for excess fluid to exit the eye and enhancing patient outcomes.

MyoScience

Series B in 2008
MyoScience Inc. engages in development and commercialization of technology driven dermatological products. MyoScience Inc. was founded in 2005 and is headquartered in Redwood City, California.

AxoGen

Post in 2007
AxoGen, Inc. engages in the development of treatment options for the repair of peripheral nerve injuries. It offers AVANCE Nerve Graft, a human allograft nerve that is used for the repair, replacement, and reconstruction of damaged peripheral nerves. The company accepts orders through phone, fax, or email. It serves surgeons. AxoGen has a strategic tissue recovery partnership with American Tissue Services Foundation (ATSF). The company was founded in 2002 and is based in Alachua, Florida.

AqueSys

Series A in 2007
AqueSys, Inc. is an ophthalmic company based in Aliso Viejo, California, that specializes in developing and commercializing innovative implantable devices for glaucoma treatment. The company's primary product, the XEN gel stent, facilitates the outflow of aqueous humor from the anterior chamber to the subconjunctival space, effectively lowering intraocular pressure in patients with glaucoma. Established in 2005, AqueSys operates as a subsidiary of Allergan plc, focusing on addressing the challenges associated with managing glaucoma through its advanced medical technology. The XEN gel stent represents a significant advancement in glaucoma treatment, providing an alternative pathway for excess fluid to exit the eye and enhancing patient outcomes.

CELLutions Biosystems

Series B in 2007
Cellutions is developing proprietary medical devices and procedures to treat cellulite, a condition that affects 90% of post-adolescent females. The company is developing a proprietary technology/procedure to be performed in an outpatient setting as a minimally invasive ‘lunchtime' treatment.

WaveTec Vision

Series B in 2007
WaveTec Vision is a small company with a big idea – and the ability and the team to achieve it. Their proprietary intraoperative aberrometer system ORange will transform and advance the emerging convergence of refractive and cataract surgery. It was founded in 1997 and headquartered in Aliso Viejo, California.

AcuFocus

Series D in 2007
AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at enhancing near vision. The company offers the KAMRA inlay, designed to assist presbyopic patients in restoring their near vision while preserving distance clarity. Additionally, AcuFocus provides the IC-8 IOL, a small aperture lens that accommodates a range of vision for cataract patients. The AcuTarget HD system serves as a diagnostic and surgical planning tool, aiding in the optimal treatment selection for various eye conditions, including LASIK and dry eye. AcuFocus markets its products through distribution partners across the Americas, Asia-Pacific, Europe, and the Middle East, thereby serving a global clientele of physicians and patients. Founded in 2001, AcuFocus continues to focus on advancing solutions for presbyopia and related vision issues.
Softscope Medical Technologies develops endoscopic products. The company is focused on developing CROS enabled device that makes passage of a colonoscope; and CROS device for small bowel enteroscopy. Softscope Medical Technologies was founded in 2003 and is based in Minnetonka, Minnesota.

NeoVista

Series C in 2006
NeoVista Inc is dedicated to the development of medical technologies that help to advance the treatment of wet age-related macular degeneration (AMD). Wet AMD affects more than 5 million people around the world and is a major cause of blindness in men and women over the age of 50. The unique technology being developed by NeoVista continues to show promise in clinical studies. It is our goal to help improve the quality of care and reduce the burden of this destructive condition on patients, physicians, and the healthcare system.

Respicardia

Series A in 2006
Respicardia (formerly Cardiac Concepts) is dedicated to improving the lives of heart failure patients by developing implantable therapies designed to improve respiratory rhythm management and cardiovascular health. The first product, the remedē® System, is an implantable stimulation device that is designed to restore a more normal breathing pattern during sleep for patients with central sleep apnea. Respicardia® is committed to improving cardiovascular health…one breath at a time™.

NeoVista

Series B in 2006
NeoVista Inc is dedicated to the development of medical technologies that help to advance the treatment of wet age-related macular degeneration (AMD). Wet AMD affects more than 5 million people around the world and is a major cause of blindness in men and women over the age of 50. The unique technology being developed by NeoVista continues to show promise in clinical studies. It is our goal to help improve the quality of care and reduce the burden of this destructive condition on patients, physicians, and the healthcare system.

Neuronetics

Series B in 2005
Neuronetics is a company dedicated to creating non-invasive therapies for psychiatric and neurological disorders through the use of MRI-strength magnetic field pulses. Established in 2003 and headquartered in Malvern, Pennsylvania, Neuronetics has achieved a significant milestone as the first company to receive FDA clearance for a non-systemic and non-invasive treatment for depression, specifically aimed at patients who have not experienced relief from previous antidepressant therapies. The company's innovative approach positions it at the forefront of developing medical devices for the treatment of mental health conditions.

LipoSonix

Series C in 2004
LipoSonix, Inc. operates as a medical device company. The company develops non-invasive body sculpting products for aesthetic applications. The company was founded in 1999 and is based in Bothell, Washington. As of July 1, 2008, LipoSonix, Inc. operates as a subsidiary of Medicis Pharmaceutical Corp.

Inogen

Series B in 2004
Inogen is innovation in oxygen therapy. Our mission is to improve freedom and independence for oxygen therapy patients through innovative products and services. As a manufacturer and Accredited Homecare Provider dedicated to oxygen therapy, Inogen is ideally suited to develop products tailored to oxygen therapy users and to provide superior service to those users in their homes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.